Please assess the completion status of the following clinical trial:

Trial Title: Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients of either gender aged 18+ years.~2. Diagnosis of chronic cerebral ischemia (CCI) based on the clinical history of underlying vascular disease(atherosclerosis and/or arterial hypertension) and neurological signs.~3. Unchanged basic therapy of CCI and underlying vascular disease for a previous 3 month.~4. Signed informed consent form.~Exclusion Criteria:~1. Other neurological diseases.~2. Any known allergy to/intolerance of any constituent of the medication.~3. Pregnancy, breast-feeding.~4. Participation in other clinical trials for 3 months prior to enrollment in this study.~5. The patient is related to the research personnel of the investigative sites that are directly involved in the study, or is the immediate relative of the investigator, or the employee of OOO NPF Materia Medica Holding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Divaza (Type: None): Oral administration. 2 tablet 3 times daily. Keep the tablets in the mouth until completely dissolved, outside of meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).